Chimaerin 2 (CHN2) (NM_004067) Human Mass Spec Standard

CAT#: PH311342

CHN2 MS Standard C13 and N15-labeled recombinant protein (NP_004058)



  View other "Chimaerin 2" proteins (3)

Need it in bulk or customized?
Get a free quote

CNY 14,250.00


货期*
5周

规格
    • 10 ug

Product images

经常一起买 (2)
Transient overexpression lysate of chimerin (chimaerin) 2 (CHN2), transcript variant 2
    • 100 ug

CNY 3,080.00


Rabbit Polyclonal Anti-CHN2 Antibody
    • 100 ul

CNY 5,250.00

Specifications

Product Data
Description CHN2 MS Standard C13 and N15-labeled recombinant protein (NP_004058)
Species Human
Expression Host HEK293
Expression cDNA Clone or AA Sequence RC211342
Predicted MW 53.9 kDa
Protein Sequence
Tag C-Myc/DDK
Purity > 80% as determined by SDS-PAGE and Coomassie blue staining
Concentration >0.05 µg/µL as determined by microplate BCA method
Labeling Method Labeled with [U- 13C6, 15N4]-L-Arginine and [U- 13C6, 15N2]-L-Lysine
Buffer 25 mM Tris-HCl, 100 mM glycine, pH 7.3
Reference Data
RefSeq NP_004058
RefSeq Size 3461
RefSeq ORF 1404
Synonyms ARHGAP3; BCH; CHN2-3; RHOGAP3
Locus ID 1124
Cytogenetics 7p14.3
Summary This gene encodes a guanosine triphosphate (GTP)-metabolizing protein that contains a phorbol-ester/diacylglycerol (DAG)-type zinc finger, a Rho-GAP domain, and an SH2 domain. The encoded protein translocates from the cytosol to the Golgi apparatus membrane upon binding by diacylglycerol (DAG). Activity of this protein is important in cell proliferation and migration, and expression changes in this gene have been detected in cancers. A mutation in this gene has also been associated with schizophrenia in men. Alternative transcript splicing and the use of alternative promoters results in multiple transcript variants. [provided by RefSeq, May 2014]
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Other Versions

Customer Reviews 
Loading...